Activities per year
Abstract
Objectives. An increased COVID-19 related morbidity and mortality has been reported in patients
with primary antibody deficiencies. Immunization may therefore be particularly important in these patients.
Specific cytokine signatures have been shown to be related to vaccine immunogenicity. Our aim was to
investigate the cytokine profile that characterize the immune response to SARS-CoV-2 antigen in vitro in
patients with primary antibody deficiency.
Materials and Methods. Study included 38 subjects: 31 patients with primary antibody deficiency
and 7 healthy controls. We reviewed patient’s clinical records to collect demographic and clinical data.
QuantiFERON tubes were used for blood collection and sample incubation with SARS-CoV-2 spikespecific antigens or negative control for further analysis of IFN-γ production using an ELISA and IL-1β,
IL-4, IL-6, IL-10, IL-15, IL-17A, IL-21, TNF-α and TGF- detection using xMAP technology.
Results. Of the 38 individuals (31.6% men; mean age 42.26, SD = 13.1), 28 patients and 7 controls
had completed the vaccination regimen with a median time 164 (IQR = 114) days after vaccination.
Overall, we found statistically significant increase in levels of INF-γ (p < 0.001), IL-10 (p = 0.002), IL15 (p = 0.008), IL-17A (p = 0.028), IL-1β (p = 0.044), but not IL-21 (p = 0.756), IL-4 (IL = 0.133),
IL-6 (p = 0.795), TNF-α (p = 0.019) and change in TGF-β (p = 0.003) levels following the SARS-CoV-2
antigen stimulation. The only statistically significant difference between the patient and control groups was
observed in the change in TGF-β levels after stimulation with SARS-CoV-2 antigen (p = 0.04): TGF-β
levels decreased by 167 pg/mL (median, IQR = 392) in the patient group and increased by 245 pg/mL
(median, IQR = 724) in the control group. Differences in cytokine profiles were observed when comparing
patient groups by comorbidities.
Conclusions. Patients with primary antibody deficiency show as rapid increase in both pro-inflammatory
and antiinflammatory cytokine levels, following in vitro stimulation with SARS-CoV-2 antigen, however,
cytokine profiles differ from those of healthy controls and between different comorbiditi es.
with primary antibody deficiencies. Immunization may therefore be particularly important in these patients.
Specific cytokine signatures have been shown to be related to vaccine immunogenicity. Our aim was to
investigate the cytokine profile that characterize the immune response to SARS-CoV-2 antigen in vitro in
patients with primary antibody deficiency.
Materials and Methods. Study included 38 subjects: 31 patients with primary antibody deficiency
and 7 healthy controls. We reviewed patient’s clinical records to collect demographic and clinical data.
QuantiFERON tubes were used for blood collection and sample incubation with SARS-CoV-2 spikespecific antigens or negative control for further analysis of IFN-γ production using an ELISA and IL-1β,
IL-4, IL-6, IL-10, IL-15, IL-17A, IL-21, TNF-α and TGF- detection using xMAP technology.
Results. Of the 38 individuals (31.6% men; mean age 42.26, SD = 13.1), 28 patients and 7 controls
had completed the vaccination regimen with a median time 164 (IQR = 114) days after vaccination.
Overall, we found statistically significant increase in levels of INF-γ (p < 0.001), IL-10 (p = 0.002), IL15 (p = 0.008), IL-17A (p = 0.028), IL-1β (p = 0.044), but not IL-21 (p = 0.756), IL-4 (IL = 0.133),
IL-6 (p = 0.795), TNF-α (p = 0.019) and change in TGF-β (p = 0.003) levels following the SARS-CoV-2
antigen stimulation. The only statistically significant difference between the patient and control groups was
observed in the change in TGF-β levels after stimulation with SARS-CoV-2 antigen (p = 0.04): TGF-β
levels decreased by 167 pg/mL (median, IQR = 392) in the patient group and increased by 245 pg/mL
(median, IQR = 724) in the control group. Differences in cytokine profiles were observed when comparing
patient groups by comorbidities.
Conclusions. Patients with primary antibody deficiency show as rapid increase in both pro-inflammatory
and antiinflammatory cytokine levels, following in vitro stimulation with SARS-CoV-2 antigen, however,
cytokine profiles differ from those of healthy controls and between different comorbiditi es.
| Original language | English |
|---|---|
| Pages (from-to) | 359 |
| Number of pages | 1 |
| Journal | Medicina (Kaunas) |
| Volume | 59 |
| Issue number | Suppl.2 |
| Publication status | Published - 2023 |
| Event | RSU Research Week 2023: Research Week 2023 Rīga Stradiņš University - Riga Stradins University, Riga, Latvia Duration: 27 Mar 2023 → 31 Mar 2023 https://rw2023.rsu.lv/general-information https://rw2023.rsu.lv |
Field of Science*
- 3.1 Basic medicine
- 3.3 Health sciences
Publication Type*
- 3.4. Other publications in conference proceedings (including local)
Access to Document
Fingerprint
Dive into the research topics of 'Cytokine Profile in Patients with Primary Antibody Deficiency in Response to SARS-CoV-2 Antigen'. Together they form a unique fingerprint.Activities
- 1 Poster presentation
-
Cytokine Profile in Patients with Primary Antibody Deficiency in Response to SARS-CoV-2 Antigen
Lucāne, Z. (Speaker), Papirte, S. (Co-author), Gersone, G. (Co-author), Straupmane, D. (Co-author), Šlisere, B. (Co-author), Vilne, B. (Co-author), Gailīte, L. (Co-author), Tretjakovs, P. (Co-author) & Kurjāne, N. (Co-author)
29 Mar 2023Activity: Talk or presentation types › Poster presentation